Clinical Trials Logo

Uterine Cervical Neoplasms clinical trials

View clinical trials related to Uterine Cervical Neoplasms.

Filter by:

NCT ID: NCT04334239 Completed - Breast Cancer Clinical Trials

Effectiveness of Care in Certified Cancer Centres in Germany

WiZen
Start date: May 1, 2017
Phase:
Study type: Observational

Assessment of the effectiveness of care in certified cancer centres for eight cancer entities via a retrospective cohort study based on secondary data from statutory health insurance funds and population-based clinical cancer registries.

NCT ID: NCT04307433 Completed - HIV/AIDS Clinical Trials

Storytelling Intervention to Promote Cervical Cancer Screening Uptakes Among Malawian Women Living With Human Immunodeficiency Virus

Start date: October 21, 2021
Phase: N/A
Study type: Interventional

To develop a theory-based culturally-grounded storytelling-based intervention to increase cervical cancer screening among Malawian women living with HIV infection. Secondary objectives: To conduct a pilot randomized clinical trial (RCT) to examine the acceptability, feasibility and preliminary effectiveness of narrative intervention on cervical cancer screening prevention behavior.

NCT ID: NCT04286243 Completed - Cervical Cancer Clinical Trials

Prevention of Cervical Cancer Through an HPV-based Screen-and-treat Strategy in Malawi

Start date: March 4, 2020
Phase: N/A
Study type: Interventional

The purpose of the study is to determine the acceptability, appropriateness, and feasibility of implementing new strategies to screen and treat eligible women for cervical cancer through a cluster randomized trial of two different models. Both models offer the same screening and treatment algorithm, but one will be based in Voluntary Family Planning (VFP) or other clinics and the second will be based in the community. Participants will be recruited from two districts in Malawi with the highest HIV prevalence in the country: Lilongwe in the Central Region and Zomba in the Southern Region.

NCT ID: NCT04269837 Completed - Clinical trials for Malignant Female Reproductive System Neoplasm

Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer

Start date: May 20, 2021
Phase: N/A
Study type: Interventional

This phase I trial studies a sexual health counseling intervention during radiation therapy in improving quality of life for women with gynecologic cancer. Women with gynecologic cancer often suffer long-term complications from treatment that can affect their physical and psychological well-being. An early sexual health counseling intervention prior to and after radiation may improve symptoms management and reduce the physical and psychological effects of treatment.

NCT ID: NCT04258553 Completed - Oxidative Stress Clinical Trials

Thiol Disulfide Balance in Cervix Cancer

Start date: September 1, 2018
Phase:
Study type: Observational

The aim of this research is to evaluate thiol‑disulfide balance in cervix cancer patients

NCT ID: NCT04246580 Completed - Cervical Cancer Clinical Trials

Evaluation of Indocyanine Green-guided Systematic Pelvic Lymphadenectomy in Endometrial and Cervical Cancer

Start date: January 2014
Phase:
Study type: Observational

The lymph nodes involvement is one of the most important prognostic factors in endometrial (EC) and cervical cancer (CC). Indeed, the lymph node involvement in cancer patients modifies the International Federation of Gynecology and Obstetrics (FIGO) stage and plays a pivotal role in the choice of the adjuvant therapy. Since the modern imaging techniques are not yet able to accurately detect lymph nodes metastasis, pelvic systematic lymphadenectomy has still an important role and it still represents the gold standard in EC and CC. The sentinel lymph node (SLN) biopsy, which is a standard practice in breast cancer and melanoma, is often used in some early stage gynaecological cancers such as EC and CC. Indocyanine green (ICG) is the most used tracer for the detection of SLN in gynaecological cancer, especially in laparoendoscopic setting. ICG allows a complete visualization of the lymphatic drainage and, for this reason, it may be used even in systematic pelvic lymphadenectomy to guide the surgeon during the procedure. Several studies have demonstrated an advantage of the ICG-guided lymphadenectomy in other types of cancers, showing a higher number of lymph nodes removed with this technique when compared to standard lymphadenectomy (without ICG). To date, there is no published study about ICG-guided systematic pelvic lymphadenectomy in EC and CC. In this scenario, the aim of this study will be to compare systematic ICG-guided pelvic lymphadenectomy and standard lymphadenectomy in EC and CC.

NCT ID: NCT04246489 Completed - Clinical trials for Uterine Cervical Neoplasms

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

Start date: March 30, 2020
Phase: Phase 2
Study type: Interventional

The main purpose of this study was to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.

NCT ID: NCT04237883 Completed - Diabetes Clinical Trials

Primary Care Clinical Excellence Incentive Study

PCCE
Start date: November 1, 2019
Phase: N/A
Study type: Interventional

As part of UCLA Health's commitment to developing a premier integrated health system built on a foundation of physician-led, team-based primary care, the Department of Medicine (DOM) recently implemented a new performance based incentive plan called the Primary Care Clinical Excellence (PCCE) Incentive Plan. This incentive plan was developed to motivate providers to improve health maintenance screening rates. The UCLA Health DOM Quality team is leading the implementation and evaluation of this new incentive plan across our primary care network. In addition, the DOM Quality team has partnered with the UCLA Anderson School of Management to study the most efficacious ways to frame and communicate performance based incentives. Understanding the factors that motivate physicians to deliver the highest quality primary care will provide pivotal insights into the successful implementation of performance based programs nationwide. The investigators believe that physicians who receive communication built on behavioral principles will demonstrate more motivation towards and success at meeting national primary care screening guidelines.

NCT ID: NCT04205799 Completed - Clinical trials for Advanced/Metastatic Cervical Cancer

Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure

CABOCOL-01
Start date: January 15, 2020
Phase: Phase 2
Study type: Interventional

Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment.

NCT ID: NCT04188860 Completed - Immunotherapy Clinical Trials

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy

Start date: December 6, 2019
Phase: Phase 2
Study type: Interventional

For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum. However, if they were refractory to platinum-based chemotherapy, there were no other more effective medications or treatment. The marketing of anti-PD-1 antibody has provided an opportunity of curative management. This single arm, open, phase II trial would recruit 34 eligible patients. A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel would be given for first 9 patients. If at least total 2 patients achieved complete or partial remission, or at least total 6 patients achieved complete or partial remission or stable disease, the same regimen would be given for rest patients. The primary end is overall response rate (ORR). The second ends include progression-free survival, overall survival, disease control rate, remission duration, and adverse events. A molecular testing, mainly consisting of genomic analysis, will be carried in the oncologic tissues.